110 Results for "

highly bioavailable

" in MedChemExpress (MCE) Product Catalog:
Products (110)

110 Results for "highly bioavailable" in MCE Product Catalog:

251
251 Publications Verification
Cat. No.: HY-15531
CAS No.: 1257044-40-8
Purity:  99.95%
Synonyms: ABT-199; GDC-0199; RG7601
Target:  

Bcl-2 Family Autophagy

Research Areas:  

Cancer

Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-10619
CAS No.: 1038915-60-4
Purity:  99.96%
Synonyms: MK-4827
Target:  

PARP Apoptosis

Research Areas:  

Cancer

Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-10619B
CAS No.: 1038915-73-9
Purity:  99.99%
Synonyms: MK-4827 tosylate
Target:  

PARP Apoptosis

Research Areas:  

Cancer

Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with an IC50 of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-10619A
CAS No.: 1038915-64-8
Purity:  99.41%
Synonyms: MK-4827 hydrochloride
Target:  

PARP Apoptosis

Research Areas:  

Cancer

Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib hydrochloride leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
86
86 Cited Publications
Cat. No.: HY-10619E
CAS No.: 1613220-15-7
Purity:  99.97%
Synonyms: MK-4827 tosylate hydrate
Target:  

PARP Apoptosis

Research Areas:  

Cancer

Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .
loading...
    loading...
59
59 Cited Publications
Cat. No.: HY-50855
CAS No.: 1009820-21-6
Synonyms: CX-4945
Target:  

Casein Kinase Autophagy

Research Areas:  

Cancer

Silmitasertib (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
loading...
    loading...
59
59 Cited Publications
Cat. No.: HY-50855B
CAS No.: 1309357-15-0
Synonyms: CX-4945 sodium salt
Target:  

Casein Kinase Autophagy

Research Areas:  

Cancer

Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
loading...
    loading...
57
57 Cited Publications
Cat. No.: HY-13026
CAS No.: 870281-82-6
Purity:  99.69%
Synonyms: CAL-101; GS-1101
Target:  

PI3K Autophagy

Research Areas:  

Cancer

Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-13238
CAS No.: 1051375-16-6
Purity:  99.85%
Synonyms: S/GSK1349572
Target:  

HIV Integrase HIV

Research Areas:  

Infection

Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-13238A
CAS No.: 1051375-19-9
Purity:  99.97%
Synonyms: S/GSK1349572 sodium
Target:  

HIV Integrase HIV

Research Areas:  

Infection

Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM) .
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-10237
CAS No.: 394730-60-0
Purity:  98.52%
Synonyms: EBP 520; SCH 503034
Target:  

HCV Protease HCV SARS-CoV

Research Areas:  

Infection

Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CL pro activity .
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-15604
CAS No.: 1204144-28-4
Purity:  99.71%
Target:  

Pim Autophagy Apoptosis

Research Areas:  

Cancer

AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-13208
CAS No.: 1071992-57-8
Purity:  98.01%
Synonyms: AT-406 hydrochloride; Debio 1143 hydrochloride; SM-406 hydrochloride
Target:  

IAP Apoptosis

Research Areas:  

Cancer

Xevinapant (AT-406) hydrochloride is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). Xevinapant hydrochloride binds to XIAP, cIAP1, and cIAP2 proteins with Kis of 66.4, 1.9, and 5.1 nM, respectively. Xevinapant hydrochloride effectively antagonizes XIAP BIR3 protein in a cell-free functional assay, induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines. Xevinapant hydrochloride is highly effective in induction of apoptosis in xenograft tumors .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-18658
CAS No.: 1448867-41-1
Synonyms: NVP-HDM201; HDM201
Research Areas:  

Cancer

Siremadlin (NVP-HDM201) is a potent, orally bioavailable and highly specific p53-MDM2 interaction inhibitor.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-117650A
CAS No.: 2072057-17-9
Purity:  99.85%
Synonyms: RO 7020322; (S)-RO0321
Target:  

HBV

Research Areas:  

Infection

RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-15785
CAS No.: 1260533-36-5
Purity:  98.79%
Synonyms: TAS-116
Target:  

HSP

Research Areas:  

Cancer

Pimitespib (TAS-116) is an oral bioavailable, ATP-competitive, highly specific HSP90α/HSP90β inhibitor (Kis of 34.7 nM and 21.3 nM, respectively) without inhibiting other HSP90 family proteins such as GRP94 . Pimitespib demonstrates less ocular toxicity .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-100818
CAS No.: 1448169-71-8
Purity:  99.65%
Synonyms: TAS-120
Target:  

FGFR

Research Areas:  

Cancer

Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-16925
CAS No.: 1857417-13-0
Research Areas:  

Cancer

MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-101340
CAS No.: 1610759-22-2
Purity:  99.77%
Synonyms: CFI-402257
Target:  

Mps1

Research Areas:  

Cancer

CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-101340A
CAS No.: 1610677-37-6
Purity:  98.91%
Synonyms: CFI-402257 hydrochloride
Target:  

Mps1

Research Areas:  

Cancer

CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity .
loading...
    loading...